Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 03:40:10 2024-04-30 am EDT 		5-day change 1st Jan Change
2.7 ILa +3.85% Intraday chart for Can-Fite BioPharma Ltd. +3.85% +3.85%
Apr. 03 Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study CI
Mar. 28 Can-Fite Biopharma Ltd. Announces Clinical Update CI

Evolution of the average Target Price on Can-Fite BioPharma Ltd.

Price target over the last 5 years

History of analyst recommendation changes

842ddba3bd871.TNUxmpwc8PPXfF3znFPC3V6mg3VC-6KZ_7zzZ00KzsQ.CYFpzNIlpL2gLQeg-iCBuW387k0ouvepienDLgwzgrIBh2D21VG4vaM1Pg~2a3cb130a4a8254b4388d39b3378055a

Analyst Recommendations on Can-Fite BioPharma Ltd.

HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating MT
CAN FITE BIOPHARMA : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target MT
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.026
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Can-Fite BioPharma Ltd.

HC Wainwright
Aegis Capital

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CANF Stock
  4. Consensus Can-Fite BioPharma Ltd.